NASDAQ:ENLV Enlivex Therapeutics - ENLV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $4.36 -0.01 (-0.23%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.30▼$4.4350-Day Range$3.74▼$4.6852-Week Range$3.62▼$8.64Volume50,214 shsAverage Volume30,982 shsMarket Capitalization$80.27 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Enlivex Therapeutics MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside244.0% Upside$15.00 Price TargetShort InterestHealthy0.99% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.68) to ($1.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.45 out of 5 starsMedical Sector966th out of 1,030 stocksPharmaceutical Preparations Industry467th out of 502 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Enlivex Therapeutics has a forecasted upside of 244.0% from its current price of $4.36.Amount of Analyst CoverageEnlivex Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.99% of the outstanding shares of Enlivex Therapeutics have been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Enlivex Therapeutics has recently decreased by 4.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEnlivex Therapeutics does not currently pay a dividend.Dividend GrowthEnlivex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENLV. Previous Next 0.7 News and Social Media Coverage News SentimentEnlivex Therapeutics has a news sentiment score of -0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.MarketBeat FollowsOnly 2 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.82% of the stock of Enlivex Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Enlivex Therapeutics are expected to grow in the coming year, from ($1.68) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enlivex Therapeutics is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enlivex Therapeutics is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnlivex Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enlivex Therapeutics (NASDAQ:ENLV) StockEnlivex Therapeutics Ltd. is a clinical stage macrophage reprogramming immunotherapy company, which develops Allocetra,a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded on January 22, 2012 and is headquartered in Nes-Ziona, Israel.Read More Receive ENLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ENLV Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comBrokers Offer Predictions for Enlivex Therapeutics Ltd.'s FY2022 Earnings (NASDAQ:ENLV)January 25, 2023 | msn.comEnlivex cleared to expand clinical trial for cell therapy candidateFebruary 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 21, 2023 | reuters.comENLV.O - | Stock Price & Latest News | ReutersJanuary 4, 2023 | ca.finance.yahoo.comEnlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and BelgiumJanuary 4, 2023 | finance.yahoo.comEnlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and BelgiumDecember 6, 2022 | uk.finance.yahoo.comWhat's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The AnswersDecember 5, 2022 | finance.yahoo.comEnlivex Announces Third Quarter 2022 Financial Results and Provides a Business UpdateFebruary 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 2, 2022 | finance.yahoo.comFirst Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTMNovember 29, 2022 | benzinga.comFDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid MalignanciesNovember 28, 2022 | finance.yahoo.comEnlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid MalignanciesNovember 15, 2022 | benzinga.comEnlivex Doses First Patient in Phase I/II Trial to Evaluate Allocetra™ for Advanced Solid Tumor TreatmentNovember 15, 2022 | benzinga.comEnlivex: Meet The Company Championing A Paradigm Shift In Cancer TreatmentNovember 15, 2022 | finance.yahoo.comEnlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid TumorsNovember 11, 2022 | finance.yahoo.comHere's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn SituationNovember 10, 2022 | finance.yahoo.comEnlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of CancerNovember 1, 2022 | benzinga.comA Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical TrialOctober 25, 2022 | proactiveinvestors.comEnlivex Therapeutics says strong cash runway will support progress of its immunotherapy candidateOctober 7, 2022 | nasdaq.comWe Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth CarefullyOctober 3, 2022 | finance.yahoo.comEnlivex to Present at the 4th Macrophage-Directed Therapies SummitSeptember 16, 2022 | morningstar.comEnlivex Therapeutics Ltd ENLV Stock ChartSeptember 13, 2022 | finance.yahoo.comEnlivex to Present at Upcoming Investor and Media ConferencesSeptember 12, 2022 | finance.yahoo.comEnlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022September 6, 2022 | finance.yahoo.comEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell TherapyAugust 29, 2022 | finance.yahoo.comEnlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor CellsAugust 24, 2022 | investing.comEnlivex Therapeutics Ltd. Misses Q2 EPS by 9cSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ENLV Company Calendar Last Earnings12/05/2022Today2/02/2023Next Earnings (Estimated)5/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENLV CUSIPN/A CIK1596812 Webwww.enlivex.com Phone(728) 662-3301FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+244.0%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.86% Return on Assets-34.31% Debt Debt-to-Equity RatioN/A Current Ratio13.08 Quick Ratio13.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.64 per share Price / Book0.94Miscellaneous Outstanding Shares18,410,000Free Float16,151,000Market Cap$80.27 million OptionableNot Optionable Beta0.99 Key ExecutivesOren HershkovitzChief Executive OfficerShachar ShlosbergerChief Financial OfficerDror MevorachChief Scientific & Medical OfficerOdelia Ben-ShitritHead-Clinical OperationsEinat GalamidiVice President-MedicalKey CompetitorsMainz Biomed B.V.NASDAQ:MYNZOramed PharmaceuticalsNASDAQ:ORMPNRx PharmaceuticalsNASDAQ:NRXPYumanity TherapeuticsNASDAQ:YMTXDecibel TherapeuticsNASDAQ:DBTXView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCBought 51,300 shares on 11/15/2022Ownership: 0.000%Renaissance Technologies LLCSold 5,300 shares on 11/14/2022Ownership: 0.321%UBS Group AGBought 13,490 shares on 11/10/2022Ownership: 0.173%Simplex Trading LLCBought 300 shares on 11/4/2022Ownership: 0.000%View All Institutional Transactions ENLV Stock - Frequently Asked Questions What is Enlivex Therapeutics' stock price forecast for 2023? 0 Wall Street analysts have issued 1-year target prices for Enlivex Therapeutics' shares. Their ENLV share price forecasts range from $15.00 to $15.00. On average, they expect the company's share price to reach $15.00 in the next year. This suggests a possible upside of 242.5% from the stock's current price. View analysts price targets for ENLV or view top-rated stocks among Wall Street analysts. How have ENLV shares performed in 2023? Enlivex Therapeutics' stock was trading at $3.9375 on January 1st, 2023. Since then, ENLV shares have increased by 11.2% and is now trading at $4.38. View the best growth stocks for 2023 here. When is Enlivex Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. View our ENLV earnings forecast. How were Enlivex Therapeutics' earnings last quarter? Enlivex Therapeutics Ltd. (NASDAQ:ENLV) posted its quarterly earnings data on Monday, December, 5th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.02. What other stocks do shareholders of Enlivex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enlivex Therapeutics investors own include VBI Vaccines (VBIV), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Fulcrum Therapeutics (FULC), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT). What is Enlivex Therapeutics' stock symbol? Enlivex Therapeutics trades on the NASDAQ under the ticker symbol "ENLV." Who are Enlivex Therapeutics' major shareholders? Enlivex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Enlivex Therapeutics? Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enlivex Therapeutics' stock price today? One share of ENLV stock can currently be purchased for approximately $4.38. How much money does Enlivex Therapeutics make? Enlivex Therapeutics (NASDAQ:ENLV) has a market capitalization of $80.64 million. The company earns $-14,470,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. How can I contact Enlivex Therapeutics? Enlivex Therapeutics' mailing address is 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR, TEL AVIV L3, 6522042. The official website for the company is www.enlivex.com. The company can be reached via phone at (728) 662-3301 or via email at info@enlivex.com. This page (NASDAQ:ENLV) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.